As of 2025-10-19, the EV/EBITDA ratio of Ionis Pharmaceuticals Inc (IONS) is -38.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IONS's latest enterprise value is 12,608.12 mil USD. IONS's TTM EBITDA according to its financial statements is -330.52 mil USD. Dividing these 2 quantities gives us the above IONS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 11.1x | 11.0x |
| Forward P/E multiples | 8.5x - 10.4x | 9.6x |
| Fair Price | (27.95) - (27.50) | (27.42) |
| Upside | -138.2% - -137.6% | -137.5% |
| Date | EV/EBITDA |
| 2025-10-17 | -38.15 |
| 2025-10-16 | -38.14 |
| 2025-10-15 | -37.81 |
| 2025-10-14 | -37.32 |
| 2025-10-13 | -36.94 |
| 2025-10-10 | -36.64 |
| 2025-10-09 | -36.79 |
| 2025-10-08 | -36.64 |
| 2025-10-07 | -36.14 |
| 2025-10-06 | -36.18 |
| 2025-10-03 | -36.25 |
| 2025-10-02 | -35.88 |
| 2025-10-01 | -34.63 |
| 2025-09-30 | -34.45 |
| 2025-09-29 | -33.83 |
| 2025-09-26 | -33.81 |
| 2025-09-25 | -33.27 |
| 2025-09-24 | -33.73 |
| 2025-09-23 | -33.07 |
| 2025-09-22 | -32.49 |
| 2025-09-19 | -32.32 |
| 2025-09-18 | -32.67 |
| 2025-09-17 | -32.40 |
| 2025-09-16 | -32.47 |
| 2025-09-15 | -32.36 |
| 2025-09-12 | -33.36 |
| 2025-09-11 | -33.78 |
| 2025-09-10 | -33.76 |
| 2025-09-09 | -33.96 |
| 2025-09-08 | -32.32 |
| 2025-09-05 | -32.43 |
| 2025-09-04 | -31.52 |
| 2025-09-03 | -32.07 |
| 2025-09-02 | -30.62 |
| 2025-08-29 | -23.46 |
| 2025-08-28 | -23.45 |
| 2025-08-27 | -23.51 |
| 2025-08-26 | -23.24 |
| 2025-08-25 | -23.07 |
| 2025-08-22 | -23.49 |
| 2025-08-21 | -23.75 |
| 2025-08-20 | -23.54 |
| 2025-08-19 | -23.38 |
| 2025-08-18 | -23.84 |
| 2025-08-15 | -24.01 |
| 2025-08-14 | -23.56 |
| 2025-08-13 | -23.68 |
| 2025-08-12 | -22.87 |
| 2025-08-11 | -22.59 |
| 2025-08-08 | -22.98 |